Respiratory therapy with intermittent positive pressure breathing (IPPB therapy) is a recognized treatment concept for obstructive respiratory disease. In case of heavily reduced ventilation reserves or pronounced respiratory failure, it is recommended to administer aerosols through inhalation.
The slow, deep inspiration supported by the respiratory therapy device always improves pulmonary ventilation, gas exchange, and aerosol deposition. The optional, adjustable exhalation stricture contributes to this as well by ensuring that poorly ventilated peripheral lung segments receive a better gas supply. This in turn has prophylactic effects, since good ventilation is the best preventative measure against infection. Furthermore, IPPB therapy can be supplemented with drug nebulization, such as bronchospasmolytic or secretolytic substances, for obstructive diseases.
Managing secretion
Another positive effect of IPPB therapy is the cough reflex it provokes, which can significantly improve the bronchial hygiene and secretolysis of patients. In addition to portable respiratory and aerosol therapy devices alpha 300 for home care, the alpha product family also includes two clinical versions (alpha 301/302), which are designed to administer oxygen via a central gas supply. As a consequence, the devices are perfectly suited to provide continued IPPB therapy for recruitment, secretion management, and drug nebulization in acute care as well as physiotherapy and general care.